|
5#

楼主 |
发表于 2015-8-13 21:26:48
|
只看该作者
' ]8 s3 H! p# o: s5 pVaccines, 6th Edition, x2 w) M& E& A! T' j' K% n4 z
! {# w m' A$ F: G, C9 ]Apply the latest vaccination knowledge with a reference that Bill Gates calls "an indispensable guide to the enhancement of the well-being of our world." Inside Vaccines, you’ll find comprehensive and current coverage of every aspect of vaccination, from the development of each vaccine to its use in reducing disease. This medical reference book offers the expert information you need to apply the very latest techniques and information in your practice.
& \8 V! o+ R" H( T$ a, z% [/ f" ~0 n
http://yun.baidu.com/share/link? ... 1&uk=38109966061 r7 v3 S" d6 L( u0 z% }
7 S' ?) \0 v0 l- u' X
SECTION 1: General aspects of vaccination
. V3 a2 j9 |6 X/ V0 C9 S# b1 A short history of vaccination 19 F' k5 ~) i, m5 R m4 h
2 Vaccine immunology 14
3 ]/ v7 s+ z v3 The vaccine industry 33
3 {0 P0 W* @, t* h K4 Vaccine manufacturing 44
+ \ c: u! m2 q( G' z0 ~8 H5 Evolution of adjuvants across the centuries 58; Z, u/ y- D5 T5 T/ h
6 Vaccine additives and manufacturing residuals in the United States:
( e6 c& d& W5 N) Flicensed vaccines 71
/ l0 [7 E% U( k! F6 m7 Passive immunization 80
8 E2 {7 z# P5 Y( m, L2 a! e! t8 General immunization practices 88
' N# T/ b4 z1 u: ?" _2 z2 Z- oSECTION 2: Licensed vaccines
* ~/ @% s! h9 z( Y9 Adenovirus vaccines 113- A5 z6 O3 D+ g# o2 [) s
10 Anthrax vaccines 127$ ]% `& f2 Y! k7 y9 N
11 Cholera vaccines 141
% {- C& X+ T/ H8 ]12 Diphtheria toxoid 153
# q, |- M$ |. p6 V9 N) S; s13 Haemophilus influenzae vaccines 167
& a! p' T# _6 p" J8 {3 N0 K1 I14 Hepatitis A vaccines 1838 s- k' c* m, d V: y/ n
15 Hepatitis B vaccines 205$ T' R4 e: ~ q- p; Q1 [6 `
16 Human papillomavirus vaccines 235
9 }. q, p/ i) H17 Inactivated influenza vaccines 2571 T0 W ?$ j; X5 S: E" D5 E
18 Influenza vaccine-live 294* C7 I( Z! p- O* N
19 Japanese encephalitis vaccines 312; F" H. K) Z7 C+ N6 @) a e
20 Measles vaccines 352
( b/ F8 G6 C2 B; P& Z; S21 Meningococcal vaccines 388
' y, F" T$ r z' k6 K22 Mumps vaccine 419 d$ O+ U4 K9 F9 e6 A% X' T1 A
23 Pertussis vaccines . 447
4 f& k7 M- A: Q( C, f" ]5 V24 Plague vaccines 493
] N6 g% m# ]% \25 Pneumococcal conjugate vaccine and pneumococcal common protein vaccines 504: U) r( ], w1 @ \) e
26 Pneumococcal polysaccharide vaccines 5422 [. l! z8 }! y& W- w
27 Poliovirus vaccine-inactivated . 573
7 N k4 ~* m# }28 Poliovirus vaccine-live 598( C8 t, Y# F5 u! U8 _0 o8 G
29 Rabies vaccines .6467 u: u' H; k* i, F- ^
30 Rotavirus vaccines . 669
% z$ ?" _3 Z0 F& U0 H! T, J- k31 Rubella vaccine 688
- o6 ~ W4 s! Y! D2 w. E' C32 Smallpox and vaccinia 718
, c! g1 \3 q9 o5 ?2 n+ I/ c8 q) f33 Tetanus toxoid 746
: o- u0 W0 v: }* Q( L1 X) N34 Tick-borne encephalitis virus vaccines 773
t3 {/ [ Z( ?35 Tuberculosis vaccines 789
) t4 a& I; v1 _1 u( o36 Typhoid fever vaccines 812) {. l4 {" p5 h, S
37 Varicella vaccine 837
$ F# t, D% B: x y+ [38 Yellow fever vaccine 870
B0 `0 x& p7 ?, I9 S0 N6 x: m% X39 Zoster vaccine 969
- ?9 F) m/ }4 o- q- \2 J' C40 Combination vaccines 981# g( x/ P. }: ]& z) O8 j! b
SECTION 3: Vaccines in development and new vaccine strategies
7 @' ?- X& G6 B& R8 U41 Biodefense and special pathogen vaccines 1008
* n/ i2 m9 q3 j- c4 x42 Therapeutic cancer vaccines 1018
8 U$ S% n+ P z0 L8 _, Y! d43 Cytomegalovirus vaccines 1032
8 b5 @* t w. K2 n0 f. K5 _4 T& }44 Dengue vaccines 10426 i/ X/ N0 G0 s8 n: o
45 Diarrhea caused by bacteria 1052
4 h8 @) N* L* U46 Ebola vaccine 1060
# V2 \# k$ u9 o3 ~0 `9 o$ ]47 Epstein-Barr virus vaccines 1068 g6 E: `1 J; v
48 Hepatitis C vaccines 10744 R, X4 `( u: N7 @& I
49 Hepatitis E vaccines 1085
+ [ Z7 ^8 H+ ~9 J' v$ I- H+ C50 Herpes simplex virus vaccines 10908 ]# d1 |7 F- z, B7 k9 U
51 Human immunodeficiency virus vaccines 1097
. J& S; U Z9 u52 Lyme disease vaccines 1122
) Q- ]: L/ S) i6 V4 {( m$ m53 Malaria vaccines 11330 W9 h) s% O. v) y, y: z3 D$ c' i
54 Noninfectious disease vaccines 11380 e; g ]+ ~3 W! J
55 Respiratory syncytial virus and parainfluenza virus vaccines 11460 S8 `8 c: z5 Q. g. \% L2 N# d9 t
56 Parasitic disease vaccines 11540 \" ^% b' Y( r" r! q9 ]+ ^
57 Staphylococcus aureus vaccines 1161
! \0 L: B. D6 r58 Streptococcus group A vaccines 11690 e' K& p# d1 E! I! }, }
59 Streptococcus group B vaccines 1176
# Z: [% U @- t$ U60 Technologies for making new vaccines 1182
' j; c) [# t' r9 W, }4 x61 Alternative vaccine delivery methods 12003 d) G' B G, h3 L& k; t( `' W
62 The development of gene-based vectors for immunization 1232
! F/ R& |2 E' ^5 h9 C& W9 MSECTION 4: Vaccination of special groups2 t! e. d. _0 x, u$ S; _6 A; V
63 Vaccination of immunocompromised hosts 1243
* ?- C' Q. ]/ u9 U% v+ H64 Vaccination of human immunodeficiency virus-infected persons 1257
3 I8 j7 Z) E0 B; O. Q65 Vaccines for international travel 1270# A6 \! Y! b4 ?3 L( _# F
66 Vaccines for health care personnel 1290: L+ S4 h L; N& |8 |
SECTION 5: Public health and regulatory issues
! }: c6 o) H* F% m0 q3 I9 T& X/ @) w67 Immunization in the United States 1310
" }, `, ^+ M6 F, C8 S68 Immunization in Europe . 1334( Q/ V2 L, F- e; |; Y/ i7 ~
69 Immunization in the Asia-Pacific region 1353
; M, j2 u" |" y; Q- y2 n, S70 Immunization in developing countries 1369) v: R- c" J# K1 G! l) u( A+ c
71 Community immunity 1395
! v! _4 z* q$ r7 _8 v72 Economic analyses of vaccine policies 1413! T6 B( L, ?$ G
73 Regulation and testing of vaccines 1427
+ } Q% R" c4 e. G/ I' u# m74 Regulation of vaccines in Europe 1447, L, t% O- J) O+ B5 {' M2 L; A
75 Regulation of vaccines in developing countries 14546 m4 Q( }$ e$ v2 p0 n
76 Vaccine safety 1464
3 [- l8 ?* _" N4 H- {: I- J77 Legal issues . 1481
" q/ U0 R7 {" Q2 Z& H0 L78 Ethics 1508, C3 \! j3 F* ^9 P3 m
/ C, Q0 e0 R7 O' d6 x" b9 r
! Z! i* B7 U( p- A) ^2 M$ b |
|